文献速递临床试验与 GCP流行病学与生物统计

乌干达9-23月龄儿童17DD黄热病疫苗五分之一与二分之一分剂量的免疫原性:4期单盲随机临床试验

Immunogenicity of fractional one-fifth and one-half doses of 17DD yellow fever vaccine compared with full dose in children aged 9-23 months in Uganda: a phase 4, single-blind, randomised clinical trial.
PubMed 文献 · Lancet · 2026-09-11

主要结局为V1(接种后4周)经50%斑块减少中和试验测定的血清转换非劣效性(5个百分点界值)。两种分剂量均达到非劣效标准,支持在供应短缺时用于疫情应对。

要点

  • 五分之一和二分之一分剂量17DD黄热病疫苗在9-23月龄儿童中诱导的初始血清转换均非劣效于全剂量。
  • 结果支持在疫苗供应短缺的疫情应对中,对幼儿使用分剂量黄热病疫苗。

核心结论

  • 两种分剂量17DD黄热病疫苗诱导初始血清转换均非劣效于全剂量。
  • 结果支持在供应短缺时对幼儿使用分剂量黄热病疫苗进行疫情应对。

研究设计与样本

  • 4期单盲随机临床试验,在乌干达三个公共卫生机构开展。
  • 按年龄分层(9-12、13-18、19-23月龄),采用区组随机化(区组大小3和6)。
  • 接种后4周(V1)、1年(V2)及13-48个月(V3)随访;主要分析为符合方案人群,并进行了意向性分析。

主要发现

  • 入组中位年龄为13月龄(IQR 11-18)。
  • 五分之一剂量与全剂量之间血清转换无差异。
  • 两种分剂量均达到5个百分点非劣效界值。

关键数值与推荐

  • 主要结局为非劣效性血清转换,界值为5个百分点,采用50%斑块减少中和试验测定。
  • 非劣效性在符合方案人群V1(接种后4周)评估。

临床怎么用

  • 在黄热病疫苗供应短缺的疫情应对中,可考虑对9-23月龄儿童使用五分之一或二分之一分剂量17DD疫苗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fractional doses of yellow fever vaccines have been shown to be safe and immunogenic in randomised controlled trials in adults and children. However, little evidence still remains in children younger than 2 years. We assessed immunogenicity of one-fifth (0·1 mL) and one-half (0·25 mL) fractional doses compared with full doses of 17DD yellow fever vaccine in children aged 9-23 months in Kampala, Uganda. METHODS: This phase 4, single-blind, randomised clinical trial evaluating fractional dose 17DD yellow fever vaccine among children was conducted at three public-sector health facilities in Uganda. Eligible participants were aged 9-23 months at enrolment, had no history of yellow fever disease or vaccination, and did not meet the exclusion criteria. Children were enrolled in three age strata: 9-12 months, 13-18 months, and 19-23 months, and were randomly assigned (1:1:1) using block randomisation (block sizes of three and six) to one-fifth (0·1 mL), one-half (0·25 mL), or full (0·5 mL) doses of the 17DD yellow fever vaccine. Participants were followed up at 4 weeks (visit 1 [V1]), 1 year (visit 2 [V2]), and 13-48 months (visit 3 [V3]) after vaccination. The primary analysis included per-protocol participants who attended within the prespecified visit window; an intention-to-treat analysis was also conducted including all randomly assigned participants with available outcome data. Participants with missing serological data were excluded from the analysis at the corresponding visit. The primary outcome was non-inferiority in seroconversion (5 percentage-point margin) at V1 measured by 50% plaque reduction neutralisation test. This study is registered with ClinicalTrials.gov, NCT03725618, and is complete. FINDINGS: Between March 26, 2019, and May 11, 2021, 1784 participants were randomly assigned to either one-fifth dose (n=600), one-half dose (n=594), or full dose (n=590). The median (IQR) age at enrolment was 13 (11-18) months. Both fractional doses met the non-inferiority criterion compared with the full dose with no difference in seroconversion between one-fifth and full doses and -0·17 (95% CI -0·52 to 0·17) difference between one-half and full doses in the per-protocol population at V1. There was no difference between the one-fifth and full doses. INTERPRETATION: Both fractional doses of 17DD yellow fever vaccine were non-inferior to full doses in inducing initial seroconversion. The results support the use of fractional dose yellow fever vaccines among young children for outbreak response during supply shortages. FUNDING: US Centers for Disease Control and Prevention.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Doshi RH, Lubega I, Muhoza P, et al. Immunogenicity of fractional one-fifth and one-half doses of 17DD yellow fever vaccine compared with full dose in children aged 9-23 months in Uganda: a phase 4, single-blind, randomised clinical trial. Lancet. 2026. PMID: 42727590. doi:10.1016/S0140-6736(26)01390-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。